This website uses cookies to improve your experience. You can opt-out if you wish. Read More

Galderma reported record full-year 2025 results, with net sales reaching $5.2bn, a 17.7% increase at constant currency. Growth was predominantly volume-driven, with a favorable product mix offsetting competitive pricing pressures. The company delivered double-digit expansion in both International markets and the US, while all three product categories outperformed their respective markets.